Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY Clinical therapeutics Pub Date : 2025-03-01 DOI:10.1016/j.clinthera.2025.01.017

Toktam Faghihi PharmD , Farahnak Assadi MD

{"title":"Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report","authors":"Toktam Faghihi PharmD , Farahnak Assadi MD","doi":"10.1016/j.clinthera.2025.01.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Febuxostat, a nonpurine selective inhibitor of xanthine oxidase has elucidated an effective urate-lowering in adults. However, data on febuxostat utility in children is limited. The present study summarizes the current knowledge on the efficacy and safety of febuxostat in children with hyperuricemia.</div></div><div><h3>Methods</h3><div>We searched PubMed, Google Scholar, Embase, and Web of Science from inception to September 2024 for studies assessing febuxostat or comparing febuxostat with allopurinol in children and adolescents with hyperuricemia with diverse etiologies. Randomized controlled trials, prospective observational, and systematic reviews, meta-analyses, and retrospective studies were included.</div></div><div><h3>Findings</h3><div>Search results illuminated three studies assessing febuxostat in children with hyperuricemia of different etiologies; including tumor lysis syndrome (TLS), asymptomatic hyperuricemia, and gout. An open-label observational study and one-retrospective study assessed febuxostat efficacy for asymptomatic hyperuricemia and gout, respectively. There was one retrospective study that compared febuxostat to allopurinol for TLS prevention.</div></div><div><h3>Implications</h3><div>Febuxostat is a promising medication that is effective in attaining the desired outcomes in children with hyperuricemia. However, existing evidence does not permit any conclusion regarding the comparative efficacy and safety of febuxostat with allopurinol in children. Future randomized clinical trials evaluating its effectiveness and safety are needed.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 5","pages":"Pages e33-e36"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Febuxostat, a nonpurine selective inhibitor of xanthine oxidase has elucidated an effective urate-lowering in adults. However, data on febuxostat utility in children is limited. The present study summarizes the current knowledge on the efficacy and safety of febuxostat in children with hyperuricemia.

Methods

We searched PubMed, Google Scholar, Embase, and Web of Science from inception to September 2024 for studies assessing febuxostat or comparing febuxostat with allopurinol in children and adolescents with hyperuricemia with diverse etiologies. Randomized controlled trials, prospective observational, and systematic reviews, meta-analyses, and retrospective studies were included.

Findings

Search results illuminated three studies assessing febuxostat in children with hyperuricemia of different etiologies; including tumor lysis syndrome (TLS), asymptomatic hyperuricemia, and gout. An open-label observational study and one-retrospective study assessed febuxostat efficacy for asymptomatic hyperuricemia and gout, respectively. There was one retrospective study that compared febuxostat to allopurinol for TLS prevention.

Implications

Febuxostat is a promising medication that is effective in attaining the desired outcomes in children with hyperuricemia. However, existing evidence does not permit any conclusion regarding the comparative efficacy and safety of febuxostat with allopurinol in children. Future randomized clinical trials evaluating its effectiveness and safety are needed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非布司他：一种从成人到儿科的降尿酸药物一个简短的报告。

目的：非布司他是一种黄嘌呤氧化酶的非嘌呤选择性抑制剂，在成人中具有有效的降尿酸作用。然而，非布司他在儿童中的应用数据有限。本研究总结了目前关于非布司他治疗儿童高尿酸血症的有效性和安全性的知识。方法：我们检索了PubMed、谷歌Scholar、Embase和Web of Science从成立到2024年9月的研究，以评估非布司他或比较非布司他与别嘌呤醇在不同病因的高尿酸血症儿童和青少年中的作用。包括随机对照试验、前瞻性观察、系统评价、荟萃分析和回顾性研究。结果：检索结果阐明了三项评估非布司他在不同病因的高尿酸血症儿童中的作用的研究；包括肿瘤溶解综合征（TLS）、无症状高尿酸血症和痛风。一项开放标签观察性研究和一项回顾性研究分别评估了非布司他对无症状高尿酸血症和痛风的疗效。有一项回顾性研究比较了非布司他和别嘌呤醇预防TLS的效果。意义：非布司他是一种很有希望的药物，对高尿酸血症儿童有效。然而，现有的证据不允许关于非布司他与别嘌呤醇在儿童中的比较有效性和安全性的任何结论。未来需要随机临床试验来评估其有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.